Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A table from a post I made the other day ROC is 95%.
Anyone who thinks that the upcoming biomarkers and FibroScan are not useful in determining fibrosis is a fool.
It's shocking that people believe AF and his total BS.
http://www.biomedcentral.com/1471-230X/10/103/table/T2
Quote:
AF said
"Only someone being paid to shill would claim Galectin is "nipping at Intercept's heels." "
This cracks me up coming from the biggest paid shill of them all.
The article states over 700,000 shares sold by insiders in the last 12 months. It was a while back but as I recall a large number of those that were sold to exercise warrants.
GALT believes the optimal dose to be 8mg/kg. These results coming tomorrow will be 4mg/kg.
I think most people are expecting an improvement from Cohort1.
AF is a real POS. Looks like many GALT investors don't do their own DD and make investment decisions from his BS.
There is a website exposing his Sh!t.
He has no education in Journalism or Science.
He has used the phrase "Snake oil scam" to describe more than one bio in the past, ya really good journalism there.
http://www.exposeadam.com
BHF???
Yes you are correct increase. Nice volume so far today people jumping back in on the PR on results coming on the 29th
Short interest continues to decrease. Short would be a scary place to be with the possible upside with upcoming results.
http://shortsqueeze.com/?symbol=GALT&submit=Short+Quote%99
I think you will like this one also
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093689/#!po=47.5000
The thing to realize is that the point of the FibroScan, FibroTest & ELF is to have it replace biopsy. Studies are showing that this is very possible.
For our Phase1 trial we do not need to have these tests diagnose the existence or degree of NASH, it is already known. All we need to see is a improvement from the beginning of the Cohort to the end of the Cohort.
That will tell all we need, the correlation of animal testing to human.
Quote:
"Worse yet, diagnostics outside of a biopsy are lacking"
Guess the author never heard of FibroTest, ELF and FibroScan.
The Sampling Error with a biopsy makes it no better than the above 3 methods, even less accurate. You would need to turn the liver into Swiss cheese to have a accurate representation of the condition of the liver.
This is the problem with Phase1, the market doesn't realize Cohort1 results showed with a reasonable % that there was some reversal. Cohort2 adds the FibroScan, will the Market catch on this time?
http://www.biomedcentral.com/1471-230X/10/103
Try not to worry about the day to day price action, if you believe in the company consider it a gift at this level and buy more.
We will have the next results in a few weeks. FibroScan should show some visual evidence of some type of reversal. The questions are how much of a reversal and how will the market react this time. Again a small number of people in the trial but if all see a positive effect with no side effect one would think the SP will be higher than it is now. Any reversal noticed is great news for the people who suffer from NASH, a light forming at the end of the tunnel for a cure.
Why would it take any "stones" to ask when TOX would start?
It takes stones to sign on the line for a cage fight. To ask a question takes no stones. Are they going to beat you to death with the answer.
I don't know all these bio's can do anything at anytime. Sometimes I sell all out, sometimes I keep the core. Just try to buy into weakness and sell into strength. I try to take everything in to account with my decisions but I guess it's a gut feeling at the time when I buy or sell. Nobody is going to pick the perfect top or bottom. I would like to build a nice sized position here at these prices it will work out good for me this time.
Not 200ma 20ma oops 200 is toast, to many colours haha
What do you think here Tom. Looks like the 200MA held up today. If it breaks down maybe 2.80 - 2.70. I might try a few bids there.
Just starting to get back in. I got some at 3.11, 3.09 & 3.08 today. Had the other half around 3.40ish last week. Seems undervalued at these prices. Not sure how much more I want yet. Let's see what happens over the next few weeks. I think I would take a bunch if it falls under 3, I think a lot of people would.
That's what I did today, double down. Can't see it going much lower but if it does I have some dry power left for some more.
This is the Russell index. I am shocked that nobody on this board realized this was going to occur today in the last seconds of close.
volume for today 2,634,205. For sure some type of deal made to keep the price down.
See if the price can get back to 15 next week, should make a little from the 17.5 Calls at that price.
INO & NNVC were also added INO 7m share up 4%. NNVC 2.9m down 3% on the day.
familyman i was thinking about your kid getting started and myself back then.......a GIC was 12+%!. The collapse of the average disposable family income from the 70's & 80's. The governments wast on behalf of the future of our children. What's a GIC these days 10x's less interest than the 80's
Where do you start these days? I have to agree with Tom the silver and gold in your hand will always put a smile on your face, just to hold something real, regardless of possible short/medium term.
The comic book baseball card thing got crushed since 08 it's paper crap. There are other things if you open your mind. I am right now drinking wine from one of my collection of many stunning 150 - 300+ Year old silver/gold wine goblets, if I were to sell any for the lowest ask price now I would still make very good profit. These cups are like GALT I might sell a few along the way but there is something special here. I treasure my Samurai one off cups not for sale, I have been collecting for years I know there value, the pleasure of owning and using something of this nature cannot be explained. The trading profit$ is the highest of my investments but like GALT not something you find everyday hold on for the big reward.
These Bio's are a hedge for me also it might sound crazy but if the market takes a down turn we will take a haircut but....the true success of GALT and other bio's has almost nothing to do with current high probability of a total train wreak in the next 5 - 15 years.
From my job and life experience I use the past to try predict the future.
I am sure you have realized this by now but everyone's perspective should be considered. In truth I have learned just as much from the observed bad or poor decisions of companies and persons, than the good ones.
Opinions and assholes we all have one.
My take on GALT is it a success more times than it fails. So if I can flip a coin and lose half on a tails or....... Make 10x's+ on heads the odds tell you to keep flipping.
GLTA
Just picked up 70 17.5 July calls.
Doing very well so far on the 35 Oct 17.5 & 20 calls I picked up a while back.
Hopeful GALT can hit 17 - 18 from the Russell influence.
I think no matter what GALT does or what the results are AF will try his best to sink us.
I would think if they follow the same protocol that it would show that the good Doctors are confidant in the upcoming results.
FamilyMan
Maybe they shouldn't say anything. Based off what happened to share price after Cohort 1, the market was expecting something more than better than expected results. I think AF was responsible for most of the damage.
If FibroScan is able to show some reversal and I consider the odds very high that it will based on the previous results, GALT should see a nice increase.
What spin will AF try this time, will he try to say that it's a bad thing that the drug is most effective in people with the worst progression of NASH.
As for the discussion of GM-CT-01 & GR-MD-02, they are the same family. What was observed in the previous trials does not mean it will correlate to GR-MD-02. What it does show for me is there is possible multiple applications for for GR-MD-02.
I just continue to dig, to reassure myself in my decision to hold the nice sized 6 figure dollar amount in GALT.
I found some interesting old PR on Davanat.
GR-MD-02 is a superior drug, the more I explore the past results the better I feel about my GALT investment.
http://www.thefreelibrary.com/Pro-Pharmaceuticals'+DAVANAT%5BR%5D+Prevents+Mucositis,+a+Serious+Side...-a0197769945
http://www.drugs.com/clinical_trials/pro-pharmaceuticals-davanat-extends-median-survival-6-7-months-end-stage-colorectal-cancer-patients-3505.html
1915000 shares short. Shorty might want to cover soon, squeeze coming?
http://shortsqueeze.com/?symbol=GALT+&submit=Short+Quote%99
As far as I understand there is no buying until the final list is released on June 27. So any effect before then is investors buying in speculation of a rise in price due to increased volume after the 27th. GALT has been rising from the 10 bottom on lower than average volume. It will be interesting to watch the price action when we do see higher volume once again.
The current run looks to be getting tired and time for some type of pullback.
I don't think GALT will pull back much, it should continue to average upward until the end of July when the next results are reported. Then if FibroScan confirms previous blood tests and a reversal is shown a nice gap up.
If GALT gets breakthrough it will be less than several years.
Jim did speak of breakthrough in a web cast a while back, he didn't give any timing but it is on the radar.
The Russell 2014 Annual Reconstitution changes will be announced on Friday, June 13 AFTER CLOSE. So have to wait for Monday see effect if any.
The better than expected cohort1 results produced downward trend so Who The F**K Knows.
The Corhort2 dose double results should be killer for NASH!!
Don't think the Market will give GALT credit, I think some larger scale Phase2 results required. Or Good possibility of breakthrough designation after Phase1 if model continues to correlate. Cohort2 should prove reversal with FibroScan unless for some bizarre reason cohort1 tests are out 180.
Simple logic.
Model correlation has been observed.
Higher dose should yield improved results, no TOX so sky is limit. It's just a matter of time.
I picked up some Oct calls a bit back, hope GALT can at least crack $20 on the cohort2 results, be nice to get back some of the beating I took on the April2014 Calls. Still having fun though.
AF and the usual suspects can't keep this down for ever, someday investors will be rewarded for the continued forward positive progress of GALT.
GLTA
I think it will take at least 1.5 years from start of TOX to start of trial. 2016 sounds about right if TOX starts before the end of 2014, there is a good chance that it will. NNVC finally has the ability to produce material on the scale required for TOX.
The good Dr's should maybe not be so optimistic when they present there timelines. To continue to blow all of them for years does not look good, the slow recover from the Pump terminator shows investors discontent in progress.
$10 would be 500+ market cap.
I don't know of any bio's in that range that are not in trials, so it appears that NNVC investors will have wait some time to get to $10.
Anyone think the addition to the Russell 2000 will have positive effect on June price?
Russell 2000 Additions
We currently anticipate 147 additions to the Russell 2000.
Many of the companies featured in the tables below are highly illiquid. As we approach the Reconstitution, the trading volumes of these companies will increase, thus partially reducing the magnitude of the comparison against the estimated passive index flows.
Figure 6: Predicted Russell 2000 Additions
Ticker Company NameWeight New R3000 Weight Net Buy Value Net Buy Shares Days to Trade
NYRT New York REIT Inc 0.1149% 0.0089% $155,592,854 14,380,116 17.0
HCT American Realty Capital Health 0.1015% 0.0079% $137,371,911 13,806,222 11.9
TROX Tronox Ltd 0.1001% 0.0078% $135,437,549 5,097,386 4.8
ASPS Altisource Portfolio Solutions SA 0.1003% 0.0078% $134,505,025 1,220,443 6.7
DOOR Masonite International Corp 0.0934% 0.0072% $126,269,228 2,397,365 9.6
GSAT Global Star Inc 0.0801% 0.0062% $108,462,217 31,347,461 9.8
ARTC ArthroCare Corp 0.0802% 0.0062% $107,701,076 2,216,072 3.7
PE Parsley Energy Inc-Class A 0.0716% 0.0056% $96,789,837 4,071,933 0.7
LPG DorianLPG Ltd 0.0696% 0.0054% $94,085,513 4,632,472 45.1
TSLX TPG Specialty Lending Inc 0.0681% 0.0053% $92,185,206 4,350,411 52.6
KODK Eastman Kodak Co 0.0525% 0.0041% $71,001,634 2,475,650 11.4
CPS Cooper-Standard Holding Inc 0.0513% 0.0040% $69,442,956 1,085,046 43.1
LQ La Quinta Holdings Inc 0.0475% 0.0037% $63,774,003 3,531,229 6.4
PLUG Plug Power Inc 0.0438% 0.0034% $59,246,871 13,619,970 0.6
NM Navios Maritime Holdings Inc 0.0427% 0.0033% $57,801,551 6,386,912 11.5
ZLC Zale Corp 0.0407% 0.0032% $54,561,385 2,595,689 1.9
ARWR Arrowhead Research Corp 0.0393% 0.0030% $52,939,375 4,208,217 3.0
NMIH NMI Holdings Inc 0.0384% 0.0030% $51,949,083 4,748,545 42.7
BCRX BioCryst Pharmaceuticals Inc 0.0375% 0.0029% $50,534,111 5,073,706 4.0
KFX Kofax Ltd 0.0363% 0.0028% $48,987,777 5,974,119 16.1
NGHC National General Holdings Corp 0.0351% 0.0027% $47,300,303 2,884,165 7.7
INO Inovio Pharmaceuticals Inc 0.0326% 0.0025% $43,739,796 19,439,909 4.3
TNET TriNet Group Inc 0.0272% 0.0021% $36,631,380 1,459,418 4.4
DHT DHT Holdings Inc 0.0266% 0.0021% $35,979,635 4,921,975 13.8
ONVO Organovo Holdings Inc 0.0260% 0.0020% $34,825,962 4,891,287 4.8
NEWM New Media Investment Group Inc 0.0253% 0.0020% $34,194,824 2,447,733 11.7
NNA Navios Maritime Acq Corp 0.0229% 0.0018% $31,017,870 8,688,479 56.0
MPAA Motorcar Parts of America Inc 0.0216% 0.0017% $29,024,466 1,218,491 6.4
COUP Coupons.com Inc 0.0215% 0.0017% $28,799,061 1,115,378 3.0
REI Ring Energy Inc 0.0214% 0.0017% $28,722,347 1,483,592 21.4
CUR Neuralstem Inc 0.0201% 0.0016% $27,020,172 6,283,761 6.7
BALT Baltic Trading Ltd 0.0198% 0.0015% $26,766,123 4,175,682 8.0
PFIS Peoples Financial Services Cor 0.0197% 0.0015% $26,728,181 545,473 50.7
IBCP Independent Bank Corp/MI 0.0182% 0.0014% $24,658,250 1,869,465 28.1
GRUB Grubhub Inc 0.0182% 0.0014% $24,428,961 716,812 1.7
UIHC United Insurance Holdings Corp 0.0176% 0.0014% $23,796,778 1,348,259 4.4
SB Safe Bulkers Inc 0.0176% 0.0014% $23,763,732 2,933,794 8.6
SNMX Senomyx Inc 0.0176% 0.0014% $23,564,139 3,435,006 6.2
PAHC Phibro Animal Health Corp 0.0168% 0.0013% $22,524,584 1,183,636 10.7
SGBK Stonegate Bank 0.0158% 0.0012% $21,339,068 821,049 34.0
HILL Dot Hill Systems Corp 0.0155% 0.0012% $20,791,237 4,846,442 10.9
ATNM Actinium Pharmaceuticals Inc 0.0145% 0.0011% $19,510,469 1,604,479 44.3
NWBO Northwest Biotherapeutics Inc 0.0145% 0.0011% $19,403,078 3,244,662 4.6
ASC Ardmore Shipping Corp 0.0142% 0.0011% $19,283,642 1,386,315 7.7
GALT Galectin Therapeutics Inc 0.0143% 0.0011% $19,159,278 1,481,769 6.5
MC Moelis & Co 0.0142% 0.0011% $19,104,153 607,252 5.8
QUIK QuickLogic Corp 0.0142% 0.0011% $18,978,022 4,454,935 4.2
FNHC Federated National Holding Co 0.0141% 0.0011% $18,963,550 809,025 5.5
PEIX Pacific Ethanol Inc 0.0140% 0.0011% $18,826,273 1,444,841 1.0
STRT Strattec Security Corp 0.0138% 0.0011% $18,534,961 280,833 13.2
VTSS Vitesse Semiconductor Corp 0.0133% 0.0010% $17,835,545 4,743,496 20.3
LEE Lee Enterprises Inc/IA 0.0132% 0.0010% $17,832,240 4,370,647 11.4
HNR Harvest Natural Resources Inc 0.0124% 0.0010% $16,751,371 3,432,658 18.3
HRTX Heron Therapeutics Inc 0.0124% 0.0010% $16,646,974 1,394,219 17.5
RDNT RadNet Inc 0.0124% 0.0010% $16,580,818 2,607,047 2.4
ONTY Oncothyreon Inc 0.0123% 0.0010% $16,488,413 5,725,144 16.6
NBS NeoStem Inc 0.0123% 0.0010% $16,471,659 2,418,746 7.9
IDRA Idera Pharmaceuticals Inc 0.0122% 0.0009% $16,393,002 5,652,759 3.0
OCLR Oclaro Inc 0.0118% 0.0009% $16,038,991 7,565,562 5.9
TAT TransAtlantic Petroleum Ltd 0.0119% 0.0009% $16,004,304 1,824,892 44.7
BPTH Bio-Path Holdings Inc 0.0119% 0.0009% $15,939,149 6,060,513 47.6
VSAR Versartis Inc 0.0117% 0.0009% $15,760,587 527,286 8.8
CSLT Castlight Health Inc 0.0117% 0.0009% $15,654,436 1,031,254 0.9
ANIP ANI Pharmaceuticals Inc 0.0117% 0.0009% $15,648,857 491,330 3.0
AGEN Agenus Inc 0.0113% 0.0009% $15,297,096 5,065,264 14.8
PTIE Pain Therapeutics Inc 0.0114% 0.0009% $15,284,018 3,087,680 10.9
GTT GTT Communications Inc 0.0112% 0.0009% $15,064,491 1,407,896 9.2
FBIZ First Business Financial Services Inc 0.0109% 0.0008% $14,784,850 321,690 17.9
CYTR CytRx Corp 0.0110% 0.0009% $14,781,088 3,536,145 2.4
FBMI Firstbank Corp/Alma MI 0.0105% 0.0008% $14,239,755 659,553 51.3
BEAT BioTelemetry Inc 0.0104% 0.0008% $13,980,628 1,904,718 4.0
CUI CUI Global Inc 0.0103% 0.0008% $13,962,324 1,682,208 8.2
BBW Build-A-Bear Workshop Inc 0.0104% 0.0008% $13,946,498 991,927 4.4
ITCI Intra-Cellular Therapies Inc 0.0104% 0.0008% $13,926,781 919,259 16.2
ZOES Zoe's Kitchen Inc 0.0103% 0.0008% $13,807,952 471,261 3.0
CLFD Clearfield Inc 0.0103% 0.0008% $13,762,941 809,585 6.1
HIL Hill International Inc 0.0102% 0.0008% $13,714,915 2,159,829 6.6
OPB Opus Bank 0.0101% 0.0008% $13,700,858 456,695 13.7
ZEN Zendesk Inc 0.0102% 0.0008% $13,640,706 853,611 1.4
MRTX Mirati Therapeutics Inc 0.0101% 0.0008% $13,531,917 632,628 21.1
BLMT BSB Bancorp Inc/MA 0.0097% 0.0008% $13,104,430 738,694 75.8
CIDM Cinedigm Corp 0.0095% 0.0007% $12,775,346 5,235,797 38.6
FRBK Republic First Bancorp Inc 0.0094% 0.0007% $12,773,886 2,554,777 17.4
IVAC Intevac Inc 0.0094% 0.0007% $12,735,956 1,728,081 27.4
AMZG American Eagle Energy Corp 0.0094% 0.0007% $12,659,106 2,075,263 8.0
AKBA Akebia Therapeutics Inc 0.0094% 0.0007% $12,580,198 517,704 5.8
PCTY Paylocity Holding Corp 0.0092% 0.0007% $12,392,357 636,485 2.4
SQBG Sequential Brands Group Inc 0.0091% 0.0007% $12,210,463 1,320,764 39.3
ESCA Escalade Inc 0.0089% 0.0007% $12,097,497 757,040 41.9
NSTG NanoString Technologies Inc 0.0090% 0.0007% $12,092,862 812,147 7.7
TWOU 2U Inc 0.0088% 0.0007% $11,880,412 822,743 4.4
ATEN A10 Networks Inc 0.0086% 0.0007% $11,572,281 1,011,563 2.6
ENZ Enzo Biochem Inc 0.0086% 0.0007% $11,524,903 2,804,113 16.0
NNVC NanoViricides Inc 0.0086% 0.0007% $11,523,650 3,255,268 15.8
OHRP Ohr Pharmaceutical Inc 0.0085% 0.0007% $11,410,793 1,339,295 4.9
OLBK Old Line Bancshares Inc 0.0083% 0.0006% $11,167,623 661,197 45.5
RGDO Regado Biosciences Inc 0.0083% 0.0006% $11,100,612 1,770,433 8.9
III Information Services Group Inc 0.0082% 0.0006% $11,019,333 2,148,018 20.3
DAVE Famous Dave's of America Inc 0.0082% 0.0006% $10,995,430 342,857 5.1
EVDY Everyday Health Inc 0.0081% 0.0006% $10,886,146 612,269 4.0
DXYN Dixie Group Inc/The 0.0081% 0.0006% $10,886,082 924,116 4.2
CLCT Collectors Universe Inc 0.0081% 0.0006% $10,809,160 522,687 7.9
KTWO K2M Group Holdings Inc 0.0079% 0.0006% $10,758,927 719,661 6.4
VTNR Vertex Energy Inc 0.0080% 0.0006% $10,702,633 1,090,992 2.4
BWEN Broadwind Energy Inc 0.0079% 0.0006% $10,680,002 958,708 4.6
OPWR OPOWER Inc 0.0078% 0.0006% $10,463,685 628,450 4.8
QTWO Q2 Holdings Inc 0.0078% 0.0006% $10,455,854 795,122 4.6
PCYG Park City Group Inc 0.0077% 0.0006% $10,342,338 850,521 10.7
SPWH Sportsman's Warehouse Holdings 0.0075% 0.0006% $10,143,245 1,098,943 5.2
AFH Atlas Financial Holdings Inc 0.0073% 0.0006% $9,763,861 661,508 5.9
ROIAK Radio One Inc 0.0073% 0.0006% $9,727,528 2,185,961 16.6
LBMH Liberator Medical Holdings Inc 0.0071% 0.0006% $9,582,513 2,596,887 19.8
DWCH Datawatch Corp 0.0070% 0.0005% $9,531,104 630,781 2.8
CSCD Cascade Microtech Inc 0.0069% 0.0005% $9,267,634 774,238 22.4
HNSN Hansen Medical Inc 0.0068% 0.0005% $9,220,087 6,272,168 7.8
KONA Kona Grill Inc 0.0066% 0.0005% $8,865,565 453,018 9.2
AMBR Amber Road Inc 0.0065% 0.0005% $8,736,793 638,654 5.4
XXII 22nd Century Group Inc 0.0064% 0.0005% $8,604,428 2,821,124 6.2
CMFN CM Finance Inc 0.0063% 0.0005% $8,528,065 610,019 8.1
IG IGI Laboratories Inc 0.0062% 0.0005% $8,290,191 1,573,091 7.7
RUBI Rubicon Project Inc/The 0.0061% 0.0005% $8,208,988 646,886 2.2
TRXC TransEnterix Inc 0.0060% 0.0005% $8,060,773 1,919,232 14.8
AKAO Achaogen Inc 0.0058% 0.0005% $7,820,808 557,435 7.2
BSTC BioSpecifics Technologies Corp 0.0058% 0.0004% $7,720,805 286,168 9.3
NYNY Empire Resorts Inc 0.0056% 0.0004% $7,506,453 1,191,501 10.0
HIVE Aerohive Networks Inc 0.0055% 0.0004% $7,412,710 744,248 5.7
FIVN Five9 Inc 0.0054% 0.0004% $7,224,171 964,509 6.8
BRDR Borderfree Inc 0.0054% 0.0004% $7,204,671 482,887 2.9
TRIV TriVascular Technologies Inc 0.0053% 0.0004% $7,127,402 445,741 17.2
USAK USA Truck Inc 0.0051% 0.0004% $6,953,796 411,467 5.9
TRUE Truecar Inc 0.0051% 0.0004% $6,884,240 628,124 1.4
PTSI PAM Transportation Services Inc 0.0050% 0.0004% $6,786,198 261,712 14.2
ALDR Alder Biopharmaceuticals Inc 0.0041% 0.0003% $5,556,903 517,403 12.7
SQBK Square 1 Financial Inc 0.0040% 0.0003% $5,422,693 287,067 4.2
QRHC Quest Resource Holding Corp 0.0039% 0.0003% $5,287,103 1,113,074 26.8
FRSH Papa Murphy's Holdings Inc 0.0038% 0.0003% $5,080,367 463,960 0.9
VTL Vital Therapies Inc 0.0037% 0.0003% $5,020,505 418,375 9.3
AGTC Applied Genetic Technologies C 0.0037% 0.0003% $4,900,156 357,676 25.5
SIF SIFCO Industries Inc 0.0036% 0.0003% $4,888,066 153,087 28.9
HEAR Parametric Sound Corp 0.0036% 0.0003% $4,776,389 464,629 2.0
PAYC Paycom Software Inc 0.0035% 0.0003% $4,741,239 355,149 3.5
SFBS Servisfirst Bancshares Inc 0.0032% 0.0002% $4,356,315 50,808 1.7
ADMS Adamas Pharmaceuticals Inc 0.0030% 0.0002% $3,965,866 222,177 3.1
HRTG Heritage Insurance Holdings 0.0026% 0.0002% $3,532,110 284,160 0.5
PFIE Profire Energy Inc 0.0025% 0.0002% $3,319,240 829,810 12.3
ARCW ARC Group Worldwide Inc 0.0018% 0.0001% $2,467,280 197,857 3.1
CRRS Corporate Resource Services Inc 0.0017% 0.0001% $2,331,222 959,351 9.5
Source: Deutsch e Bank, Russell, Bloomberg
Agora is recommending to sell from the breakthrough letter.
I think I will hang on and pickup some more if we drop.
Dear Breakthrough Technology Alert Reader,
Something may be wrong at Innovio. The company appears to be preparing investors for less than ideal results for its DNA vaccine VGX-3100, which is in phase 2 trials to treat women who have cervical precancerous cells.
Innovio’s stock soared after a 4-1 reverse split Friday and the announcement this week of a new trial for immune therapy to treat neck and head cancers. Then it began tumbling after the company’s CEO gave an interview that seemed to be backpedaling expectations.
We are up more 140% on the stock from the original buy-in price of $3.84 (adjusted for the 4-1 split) based on yesterday’s close. The stock could unwind well below that price if the company indeed has less than stellar results to report on VGX-3100. Results are expected any day now.
I still believe Inovio has a bright future, and I reinforced my opinion two days ago. But too much hinges on VGX-3100, and I believe we have been warned. The company has another phase 2 trial that is stalled for lack of a sponsor, two phase 1 studies for infectious diseases (HIV and influenza) that are not recruiting patients (not a good sign) and one phase 1 study for Hepatitus C that is ongoing but the therapy is designed to be a second-line treatment and Gilead Sciences already has a phenomenal Hep C drug on the market and at least one other company may soon score success with yet another Hep C drug. Inovio’s new head and neck cancer study announced this week also is based on VGX-3100. That therapy has been the bright star of the company and the stock price is built around it.
I believe it would be wise to protect the profits we have. If the company announces good results on VGX-3100 in a few days, we’ll consider jumping back in when the drama dies down.
Recommendation: Sell Inovio (NYSE: INO) immediately.
Stephen Petranek
This board has changed from the exchange of useful information to people just posting lies and BS.
I think it will be about 1.5 years from start of TOX until start of trial. The Dr's are slow but they will get there someday.
For starting in phase 1 or phase 2 for Lung and Kidney is a question I think only the FDA can answer. You would think Phase 2 since the primary goal of typical phase 1 is for safety and it will be the same drug.
GALT is already showing a very broad range with this drug. Having effects on different organs Liver, kidney, lung. Then you consider effect on Cancer something completely different than organ scaring. There are many possible applications to explore between NASH and Melanoma.
I think many years will be spent exploring to find its full potential.
Yes fast track for PBC for drug OCA, same one used in there NASH trial.
GALT still follows ICPT like a lost puppy. Today GALT is up more than ICPT on there news.
https://ca.finance.yahoo.com/q/ta?s=GALT&t=5d&l=on&z=l&q=l&p=&a=&c=ICPT
ICPT has received fast track with P2 data.
http://online.wsj.com/article/BT-CO-20140528-711952.html
GALT was just beginning P1 when it was awarded fast track.
This shows higher probability, of a greater potential for GALT's drug over ICPT's.
C1 results showed us that human is following animal model. If FibroScan was used in C1 it would have shown some type of reversal. It was smart not to have it in C1 so as not to set bar to high. FibroScan is coming in C2 like a Math proof, 2 independent methods are needed. Then hopefully investors will be rewarded for their patience.
I recall Jim talking about Breakthrough in a web cast a while ago. I am not sure how much data is required for this. Based off PVCT recent events, GALT has to be careful with the time in its trials when it submits application. One would think if P1 shows most people are cured or substantial reversal with no side effect that would be enough.
JMHO
I was referring to the Oct Calls, since results will be out long before then.
I just started to pick up a few.
Noticed there are Oct 35, 40 & 45 Calls, the highest I have seen for GALT.
Hopping good results will have positive effect on the price this time.
Do you think GALT will go up?
I would think to $50 at least but not sure if the market is that smart.
I have a few bids on the Oct calls, getting time to start picking some up.
Are you in again?